149 related articles for article (PubMed ID: 15502045)
1. Electron microscopic evaluations of clot morphology during thrombelastography.
Kawasaki J; Katori N; Kodaka M; Miyao H; Tanaka KA
Anesth Analg; 2004 Nov; 99(5):1440-1444. PubMed ID: 15502045
[TBL] [Abstract][Full Text] [Related]
2. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography.
Katori N; Tanaka KA; Szlam F; Levy JH
Anesth Analg; 2005 Jun; 100(6):1781-1785. PubMed ID: 15920213
[TBL] [Abstract][Full Text] [Related]
3. Different effects of abciximab and cytochalasin D on clot strength in thrombelastography.
Lang T; Toller W; Gütl M; Mahla E; Metzler H; Rehak P; März W; Halwachs-Baumann G
J Thromb Haemost; 2004 Jan; 2(1):147-53. PubMed ID: 14717978
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
Mousa SA; Khurana S; Forsythe MS
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
[TBL] [Abstract][Full Text] [Related]
5. The effects of cytochalasin D and abciximab on hemostasis in canine whole blood assessed by thromboelastography and the PFA-100® platelet function analyzer system.
Brainard BM; Abed JM; Koenig A
J Vet Diagn Invest; 2011 Jul; 23(4):698-703. PubMed ID: 21908311
[TBL] [Abstract][Full Text] [Related]
6. Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes.
Lu D; Owens J; Kreutz RP
Thromb Res; 2013 Aug; 132(2):e94-8. PubMed ID: 23920429
[TBL] [Abstract][Full Text] [Related]
7. Use of abciximab-modified thrombelastography in patients undergoing cardiac surgery.
Kettner SC; Panzer OP; Kozek SA; Seibt FA; Stoiser B; Kofler J; Locker GJ; Zimpfer M
Anesth Analg; 1999 Sep; 89(3):580-4. PubMed ID: 10475284
[TBL] [Abstract][Full Text] [Related]
8. Near-site monitoring of the antiplatelet drug abciximab using the Hemodyne analyzer and modified thrombelastograph.
Greilich PE; Alving BM; Longnecker D; Carr ME; Whitten CW; Chang AS; Reid TJ
J Cardiothorac Vasc Anesth; 1999 Feb; 13(1):58-64. PubMed ID: 10069286
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of different functional fibrinogen polymerization assays in eliminating platelet contribution to clot strength in thromboelastometry.
Schlimp CJ; Solomon C; Ranucci M; Hochleitner G; Redl H; Schöchl H
Anesth Analg; 2014 Feb; 118(2):269-276. PubMed ID: 24445628
[TBL] [Abstract][Full Text] [Related]
10. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography.
Khurana S; Mattson JC; Westley S; O'Neill WW; Timmis GC; Safian RD
J Lab Clin Med; 1997 Oct; 130(4):401-11. PubMed ID: 9358079
[TBL] [Abstract][Full Text] [Related]
11. A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients.
Greilich PE; Alving BM; O'Neill KL; Chang AS; Reid TJ
Anesth Analg; 1997 Jan; 84(1):31-8. PubMed ID: 8988995
[TBL] [Abstract][Full Text] [Related]
12. Is platelet function as measured by Thrombelastograph monitoring in whole blood affected by platelet inhibitors?
Bailey LA; Sistino JJ; Uber WE
J Extra Corpor Technol; 2005 Mar; 37(1):43-7. PubMed ID: 15804156
[TBL] [Abstract][Full Text] [Related]
13. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis.
Collet JP; Montalescot G; Lesty C; Soria J; Mishal Z; Thomas D; Soria C
Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):142-8. PubMed ID: 11145946
[TBL] [Abstract][Full Text] [Related]
14. Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation.
Barua RS; Sy F; Srikanth S; Huang G; Javed U; Buhari C; Margosan D; Ambrose JA
Arterioscler Thromb Vasc Biol; 2010 Jan; 30(1):75-9. PubMed ID: 19815816
[TBL] [Abstract][Full Text] [Related]
15. Assessing platelet and fibrinogen contribution to clot strength using modified thromboelastography in pregnant women.
Gottumukkala VN; Sharma SK; Philip J
Anesth Analg; 1999 Dec; 89(6):1453-5. PubMed ID: 10589626
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Methodology for Calculating Platelet Contribution to Clot Strength (Platelet Component) in Thromboelastometry and Thrombelastography.
Solomon C; Ranucci M; Hochleitner G; Schöchl H; Schlimp CJ
Anesth Analg; 2015 Oct; 121(4):868-878. PubMed ID: 26378699
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of thrombelastographic platelet-mapping in healthy cats.
Blois SL; Banerjee A; Wood RD
Vet Clin Pathol; 2012 Jun; 41(2):223-7. PubMed ID: 22452748
[TBL] [Abstract][Full Text] [Related]
18. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.
Jámbor C; Reul V; Schnider TW; Degiacomi P; Metzner H; Korte WC
Anesth Analg; 2009 Oct; 109(4):1023-8. PubMed ID: 19762725
[TBL] [Abstract][Full Text] [Related]
19. Thrombelastograph (TEG) analysis of platelet gel formed with different thrombin concentrations.
Ellis WC; Cassidy LK; Finney AS; Spiwak AJ; Riley JB
J Extra Corpor Technol; 2005 Mar; 37(1):52-7. PubMed ID: 15804158
[TBL] [Abstract][Full Text] [Related]
20. Clot Formation Is Associated With Fibrinogen and Platelet Forces in a Cohort of Severely Injured Emergency Department Trauma Patients.
White NJ; Newton JC; Martin EJ; Mohammed BM; Contaifer D; Bostic JL; Brophy GM; Spiess BD; Pusateri AE; Ward KR; Brophy DF
Shock; 2015 Aug; 44 Suppl 1(0 1):39-44. PubMed ID: 25643013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
